Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
- PMID: 23776246
- PMCID: PMC3704038
- DOI: 10.1073/pnas.1305321110
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Abstract
Oxaliplatin is an integral component of colorectal cancer therapy, but its clinical use is associated with a dose-limiting peripheral neurotoxicity. We found that the organic cation transporter 2 (OCT2) is expressed on dorsal root ganglia cells within the nervous system where oxaliplatin is known to accumulate. Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity. Furthermore, genetic or pharmacologic knockout of Oct2 protected mice from hypersensitivity to cold or mechanical-induced allodynia, which are established tests to assess acute oxaliplatin-induced neurotoxicity. These findings provide a rationale for the development of targeted approaches to mitigate this debilitating toxicity.
Keywords: chemotherapy; neuropathy; solute carriers.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity.Toxicology. 2021 Jul;459:152853. doi: 10.1016/j.tox.2021.152853. Epub 2021 Jul 9. Toxicology. 2021. PMID: 34252480
-
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.J Clin Invest. 2020 Sep 1;130(9):4601-4606. doi: 10.1172/JCI136796. J Clin Invest. 2020. PMID: 32484793 Free PMC article.
-
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.J Pharmacol Exp Ther. 2011 Aug;338(2):537-47. doi: 10.1124/jpet.111.181297. Epub 2011 May 23. J Pharmacol Exp Ther. 2011. PMID: 21606177
-
Platinum accumulation in oxaliplatin-induced peripheral neuropathy.J Peripher Nerv Syst. 2021 Mar;26(1):35-42. doi: 10.1111/jns.12432. Epub 2021 Jan 27. J Peripher Nerv Syst. 2021. PMID: 33462873 Free PMC article. Review.
-
Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests.Anticancer Drugs. 2013 Nov;24(10):1069-78. doi: 10.1097/CAD.0000000000000002. Anticancer Drugs. 2013. PMID: 24025562 Review.
Cited by
-
Role of Organic Cation Transporter 2 in Autophagy Induced by Platinum Derivatives.Int J Mol Sci. 2022 Jan 19;23(3):1090. doi: 10.3390/ijms23031090. Int J Mol Sci. 2022. PMID: 35163014 Free PMC article.
-
Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.J Exp Clin Cancer Res. 2021 Oct 22;40(1):331. doi: 10.1186/s13046-021-02141-z. J Exp Clin Cancer Res. 2021. PMID: 34686205 Free PMC article. Review.
-
Noninvasive peroneal sensory and motor nerve conduction recordings in the rabbit distal hindlimb: feasibility, variability and neuropathy measure.PLoS One. 2014 Mar 21;9(3):e92694. doi: 10.1371/journal.pone.0092694. eCollection 2014. PLoS One. 2014. PMID: 24658286 Free PMC article.
-
The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes.Molecules. 2021 Sep 16;26(18):5629. doi: 10.3390/molecules26185629. Molecules. 2021. PMID: 34577099 Free PMC article. Review.
-
Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Aug 1;1179:122882. doi: 10.1016/j.jchromb.2021.122882. Epub 2021 Jul 30. J Chromatogr B Analyt Technol Biomed Life Sci. 2021. PMID: 34365291 Free PMC article.
References
-
- Cascinu S, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478–3483. - PubMed
-
- Gamelin L, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12 Pt 1):4055–4061. - PubMed
-
- Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol. 2010;15(1):82–87. - PubMed
-
- Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007;25(25):4028–4029. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials